Tags

Type your tag names separated by a space and hit enter

A randomized clinical trial to determine the efficacy of manufacturers' recommended doses of omega-3 fatty acids from different sources in facilitating cardiovascular disease risk reduction.
Lipids Health Dis. 2014 Jun 21; 13:99.LH

Abstract

BACKGROUND

Omega-3 fatty acids confer beneficial health effects, but North Americans are lacking in their dietary omega-3-rich intake. Supplementation is an alternative to consumption of fish; however, not all omega-3 products are created equal. The trial objective was to compare the increases in blood levels of omega-3 fatty acids after consumption of four different omega-3 supplements, and to assess potential changes in cardiovascular disease risk following supplementation.

METHODS

This was an open-label, randomized, cross-over study involving thirty-five healthy subjects. Supplements and daily doses (as recommended on product labels) were:Concentrated Triglyceride (rTG) fish oil: EPA of 650 mg, DHA of 450 mgEthyl Ester (EE) fish oil: EPA of 756 mg, DHA of 228 mgPhospholipid (PL) krill oil: EPA of 150 mg, DHA of 90 mgTriglyceride (TG) salmon oil: EPA of 180 mg, DHA of 220 mg.Subjects were randomly assigned to consume one of four products, in random order, for a 28-day period, followed by a 4-week washout period. Subsequent testing of the remaining three products, followed by 4-week washout periods, continued until each subject had consumed each of the products. Blood samples before and after supplementation were quantified for fatty acid analysis using gas chromatography, and statistically analysed using ANOVA for repeated measures.

RESULTS

At the prescribed dosage, the statistical ranking of the four products in terms of increase in whole blood omega-3 fatty acid levels was concentrated rTG fish oil > EE fish oil > triglyceride TG salmon oil > PL krill oil. Whole blood EPA percentage increase in subjects consuming concentrated rTG fish oil was more than four times that of krill and salmon oil. Risk reduction in several elements of cardiovascular disease was achieved to a greater extent by the concentrated rTG fish oil than by any other supplement. Krill oil and (unconcentrated) triglyceride oil were relatively unsuccessful in this aspect of the study.

CONCLUSION

For the general population, the form and dose of omega-3 supplements may be immaterial. However, given these results, the form and dose may be important for those interested in reducing their risk of cardiovascular disease.

TRIAL REGISTRATION

ClinicalTrials.gov: NCT01960660.

Authors+Show Affiliations

Nutrasource Diagnostic Inc,, 120 Research Lane, University of Guelph Research Park, Suite 203, Guelph N1G0B4, Ontario, Canada. mlaidlaw@nutrasource.ca.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

24952576

Citation

Laidlaw, Maggie, et al. "A Randomized Clinical Trial to Determine the Efficacy of Manufacturers' Recommended Doses of Omega-3 Fatty Acids From Different Sources in Facilitating Cardiovascular Disease Risk Reduction." Lipids in Health and Disease, vol. 13, 2014, p. 99.
Laidlaw M, Cockerline CA, Rowe WJ. A randomized clinical trial to determine the efficacy of manufacturers' recommended doses of omega-3 fatty acids from different sources in facilitating cardiovascular disease risk reduction. Lipids Health Dis. 2014;13:99.
Laidlaw, M., Cockerline, C. A., & Rowe, W. J. (2014). A randomized clinical trial to determine the efficacy of manufacturers' recommended doses of omega-3 fatty acids from different sources in facilitating cardiovascular disease risk reduction. Lipids in Health and Disease, 13, 99. https://doi.org/10.1186/1476-511X-13-99
Laidlaw M, Cockerline CA, Rowe WJ. A Randomized Clinical Trial to Determine the Efficacy of Manufacturers' Recommended Doses of Omega-3 Fatty Acids From Different Sources in Facilitating Cardiovascular Disease Risk Reduction. Lipids Health Dis. 2014 Jun 21;13:99. PubMed PMID: 24952576.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A randomized clinical trial to determine the efficacy of manufacturers' recommended doses of omega-3 fatty acids from different sources in facilitating cardiovascular disease risk reduction. AU - Laidlaw,Maggie, AU - Cockerline,Carla A, AU - Rowe,William J, Y1 - 2014/06/21/ PY - 2014/02/28/received PY - 2014/06/17/accepted PY - 2014/6/23/entrez PY - 2014/6/24/pubmed PY - 2014/12/15/medline SP - 99 EP - 99 JF - Lipids in health and disease JO - Lipids Health Dis VL - 13 N2 - BACKGROUND: Omega-3 fatty acids confer beneficial health effects, but North Americans are lacking in their dietary omega-3-rich intake. Supplementation is an alternative to consumption of fish; however, not all omega-3 products are created equal. The trial objective was to compare the increases in blood levels of omega-3 fatty acids after consumption of four different omega-3 supplements, and to assess potential changes in cardiovascular disease risk following supplementation. METHODS: This was an open-label, randomized, cross-over study involving thirty-five healthy subjects. Supplements and daily doses (as recommended on product labels) were:Concentrated Triglyceride (rTG) fish oil: EPA of 650 mg, DHA of 450 mgEthyl Ester (EE) fish oil: EPA of 756 mg, DHA of 228 mgPhospholipid (PL) krill oil: EPA of 150 mg, DHA of 90 mgTriglyceride (TG) salmon oil: EPA of 180 mg, DHA of 220 mg.Subjects were randomly assigned to consume one of four products, in random order, for a 28-day period, followed by a 4-week washout period. Subsequent testing of the remaining three products, followed by 4-week washout periods, continued until each subject had consumed each of the products. Blood samples before and after supplementation were quantified for fatty acid analysis using gas chromatography, and statistically analysed using ANOVA for repeated measures. RESULTS: At the prescribed dosage, the statistical ranking of the four products in terms of increase in whole blood omega-3 fatty acid levels was concentrated rTG fish oil > EE fish oil > triglyceride TG salmon oil > PL krill oil. Whole blood EPA percentage increase in subjects consuming concentrated rTG fish oil was more than four times that of krill and salmon oil. Risk reduction in several elements of cardiovascular disease was achieved to a greater extent by the concentrated rTG fish oil than by any other supplement. Krill oil and (unconcentrated) triglyceride oil were relatively unsuccessful in this aspect of the study. CONCLUSION: For the general population, the form and dose of omega-3 supplements may be immaterial. However, given these results, the form and dose may be important for those interested in reducing their risk of cardiovascular disease. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01960660. SN - 1476-511X UR - https://www.unboundmedicine.com/medline/citation/24952576/A_randomized_clinical_trial_to_determine_the_efficacy_of_manufacturers'_recommended_doses_of_omega_3_fatty_acids_from_different_sources_in_facilitating_cardiovascular_disease_risk_reduction_ L2 - https://lipidworld.biomedcentral.com/articles/10.1186/1476-511X-13-99 DB - PRIME DP - Unbound Medicine ER -